Medicine · 2023
Secukinumab for the treatment of generalized pustular psoriasis: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Jiayan, Gao Xue, Ma Lili, Fang Yimiao
Аннотация
INTRODUCTION: Generalized pustular psoriasis (GPP) is a rare subtype of psoriasis that manifests as a generalized pustular eruption.
PATIENT CONCERNS: A 31-year-old female was admitted to the hospital in June 2021 with a widespread erythematous, itchy, and scaly rash for a week. The patient has a 10-year history of psoriasis vulgaris.
DIAGNOSIS: GPP complicated by a late-stage viral infection and early-stage renal damage.
INTERVENTIONS: Weekly subcutaneous injections of 300 mg of secukinumab for a month, followed by monthly (every 4 weeks) injections of 300 mg of secukinumab for 20 weeks.
OUTCOMES: The symptoms of pustules and erythema were reduced, and the patient reported pain relief soon after the first injection. The patient had no serious adverse reactions during treatment and follow-up.
CONCLUSIONS: Secukinumab might be an optional treatment strategy for GPP.
PATIENT CONCERNS: A 31-year-old female was admitted to the hospital in June 2021 with a widespread erythematous, itchy, and scaly rash for a week. The patient has a 10-year history of psoriasis vulgaris.
DIAGNOSIS: GPP complicated by a late-stage viral infection and early-stage renal damage.
INTERVENTIONS: Weekly subcutaneous injections of 300 mg of secukinumab for a month, followed by monthly (every 4 weeks) injections of 300 mg of secukinumab for 20 weeks.
OUTCOMES: The symptoms of pustules and erythema were reduced, and the patient reported pain relief soon after the first injection. The patient had no serious adverse reactions during treatment and follow-up.
CONCLUSIONS: Secukinumab might be an optional treatment strategy for GPP.